Literature DB >> 31044348

Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".

R Brett McQueen1, Melanie D Whittington2, Rick H Chapman3, Varun M Kumar3, Jonathan D Campbell2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31044348     DOI： 10.1007/s40273-019-00802-8

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

1.  Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer.

Authors:  Robert Hettle; John Posnett; John Borrill
Journal:  J Med Econ       Date:  2015-04-07       Impact factor: 2.448

2.  Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Paul Tappenden; Sue Harnan; Shijie Ren; Praveen Thokala; Ruth Wong; Clara Mukuria; Clare Green; Simon Pledge; John Tidy
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

3.  Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Philip Rowe; Elizabeth Lowe; Darren Hodgson; Mika A Sovak; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2016-09-09       Impact factor: 41.316

4.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Euan Macpherson; Claire Watkins; James Carmichael; Ursula Matulonis
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

5.  Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.

Authors:  Holly Guy; Lydia Walder; Mark Fisher
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981
  5 in total
  2 in total

1.  Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.

Authors:  Holly Guy; Lydia Walder; Mark Fisher
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 2.  A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Authors:  Wei Gao; Dominic Muston; Matthew Monberg; Kimmie McLaurin; Robert Hettle; Elizabeth Szamreta; Elyse Swallow; Su Zhang; Iden Kalemaj; James Signorovitch; R Brett McQueen
Journal:  Pharmacoeconomics       Date:  2020-11       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.